← Eichor
Study identifier: NCT06673498 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery

Condition: Thrombocytopenia  ·  Sponsor: Anhui Provincial Hospital

PhasePhase 2
Planned participants60
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To assess the efficacy and safety of lusutrombopag combined with recombinant human thrombopoietin for the treatment of thrombocytopenia in patients with chronic liver disease destined to undergo elective invasive surgery.

This description comes directly from the study's public registry record.

Talk to the study team

Ji-Zhou Wang  ·  +86 13836135864  ·  wangjoe@ustc.edu.cn

Always discuss trial participation with your own doctor first.

Locations (2)

No.2 People's Hospital of Fuyang cityFuyang, Anhui, ChinaRecruiting
Anhui province hospitalHefei, Anhui, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06673498